Project 1
Non-small cell lung cancer (NSCLC) with non-resistant rare EGFR mutations
Phase IIbActive (also FDA-cleared for U.S. studies)
Key Facts
Indication
Non-small cell lung cancer (NSCLC) with non-resistant rare EGFR mutations
Phase
Phase IIb
Status
Active (also FDA-cleared for U.S. studies)
Company
About Suzhou Teligene
Clinical-stage Chinese biotech developing brain-penetrant small molecule targeted therapies for oncology, with multiple programs in Phase I-II trials.
View full company profile